
Evogene Ltd. EVGN
$ 0.8
-1.43%
Annual report 2024
added 03-07-2026
Evogene Ltd. Long Term Debt Current 2011-2026 | EVGN
Annual Long Term Debt Current Evogene Ltd.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 589 K | 853 K | 884 K | 974 K | 777 K | 895 K | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 974 K | 589 K | 829 K |
Long Term Debt Current of other stocks in the Biotechnology industry
| Issuer | Long Term Debt Current | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M | ||
|
Aptorum Group Limited
APM
|
433 K | $ 0.79 | -1.15 % | $ 4.31 M | ||
|
Acorda Therapeutics
ACOR
|
1.59 M | - | -24.86 % | $ 820 K | ||
|
AbCellera Biologics
ABCL
|
5.82 M | $ 3.49 | 0.58 % | $ 1.04 B | ||
|
Frequency Therapeutics
FREQ
|
2.67 M | - | - | $ 528 M | ||
|
argenx SE
ARGX
|
6.53 M | $ 700.45 | -1.19 % | $ 25 B | ||
|
I-Mab
IMAB
|
8.06 M | - | - | $ 866 M | ||
|
AgeX Therapeutics
AGE
|
428 K | - | -10.17 % | $ 12.2 K | ||
|
Alterity Therapeutics Limited
ATHE
|
57.6 K | $ 3.6 | 1.41 % | $ 8.66 B | ||
|
Grifols, S.A.
GRFS
|
117 M | $ 7.81 | -2.01 % | $ 6.83 B | ||
|
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | ||
|
Ascendis Pharma A/S
ASND
|
14.2 M | $ 225.98 | -1.32 % | $ 5 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.27 M | - | - | $ 26.5 M | ||
|
ADC Therapeutics SA
ADCT
|
1.1 M | $ 4.13 | -5.06 % | $ 105 M | ||
|
Adverum Biotechnologies
ADVM
|
5.67 M | - | - | $ 86.2 M | ||
|
Akouos
AKUS
|
671 K | - | 0.23 % | $ 488 M | ||
|
Advaxis
ADXS
|
166 K | - | -9.65 % | $ 45.9 M | ||
|
Allena Pharmaceuticals
ALNA
|
317 K | - | 3.16 % | $ 1.9 M | ||
|
Aileron Therapeutics
ALRN
|
48 K | - | 10.36 % | $ 9.8 M | ||
|
BioCardia
BCDA
|
333 K | $ 1.26 | -0.79 % | $ 26.7 M | ||
|
AlloVir
ALVR
|
10.8 M | - | 4.14 % | $ 49.1 M | ||
|
Applied Molecular Transport
AMTI
|
4.64 M | - | - | $ 10.1 M | ||
|
Anika Therapeutics
ANIK
|
1.6 M | $ 14.2 | -0.7 % | $ 208 M | ||
|
Aptose Biosciences
APTO
|
428 K | - | -45.71 % | $ 1.2 M | ||
|
Acer Therapeutics
ACER
|
104 K | - | 2.71 % | $ 14 M | ||
|
ARCA biopharma
ABIO
|
213 K | - | 1052.0 % | $ 415 M | ||
|
Aeterna Zentaris
AEZS
|
271 K | - | 5.93 % | $ 314 M | ||
|
Athersys
ATHX
|
1.01 M | - | 3.77 % | $ 22.4 M | ||
|
BioNTech SE
BNTX
|
45 M | $ 91.19 | 1.21 % | $ 27.2 B | ||
|
Aptinyx
APTX
|
337 K | - | -39.0 % | $ 4.57 M | ||
|
Autolus Therapeutics plc
AUTL
|
5.05 M | $ 1.44 | -1.37 % | $ 367 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
4.21 M | $ 6.68 | -4.57 % | $ 183 M | ||
|
Acasti Pharma
ACST
|
75 K | - | 4.01 % | $ 150 M | ||
|
AVEO Pharmaceuticals
AVEO
|
11 K | - | - | $ 521 M | ||
|
Ayala Pharmaceuticals
AYLA
|
419 K | - | - | $ 7.46 M | ||
|
Aytu BioScience
AYTU
|
137 K | $ 2.54 | -5.22 % | $ 16 M | ||
|
Certara
CERT
|
3.92 M | $ 6.67 | 1.6 % | $ 1.07 B | ||
|
Athira Pharma
ATHA
|
414 K | - | - | $ 269 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
43 K | $ 3.6 | -4.0 % | $ 7.83 B | ||
|
CureVac N.V.
CVAC
|
3.47 M | - | - | $ 867 M | ||
|
Aravive
ARAV
|
2.2 M | - | -13.39 % | $ 1.45 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
549 K | - | -2.5 % | $ 5.88 M |